To test the potential of plasma AEVs as a biomarker to differentiate PD from other forms of parkinsonism, the Apogee assays previously developed by us for CSF [39] and plasma [40] samples were optimized to measure the GLT-1+ and α-syn+ EVs in plasma. The gene discussed is SLC1A2; the disease is Parkinson disease.